secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001493152-25-008617
Event type: regulatory
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NYSE American accepts AIM ImmunoTech's plan to regain listing compliance; deadline June 11, 2026
--------------------------------------------------------------------------------

- Plan accepted under Sections 1003(a)(ii) and 1003(a)(iii) of NYSE American Company Guide.
- AIM has until June 11, 2026 to meet minimum stockholders' equity requirements.
- CEO Thomas K. Equels expressed confidence in executing the strategy.
- Company continues oncology and antiviral pipeline development alongside compliance efforts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315225008617/0001493152-25-008617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315225008617/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer